Archive · 31 Aug 2026
Emcure Pharmaceuticals Stock Seen Rising Toward ₹2,100
Emcure Pharmaceuticals’ share price has generally been moving upward for a long time.
It recently fell after reaching ₹2,047.40 on August 10.
The analysis says the upward trend may continue if the price stays above ₹1,850 and ₹1,780.
Investors could consider buying around ₹1,871.
They could buy more if the price falls toward ₹1,800.
The suggested final price target is ₹2,100 by the end of the year.
A stop-loss is suggested to limit losses if the price falls too much.
The recommendation is based on chart analysis, and trading can still result in losses.
Emcure Pharmaceuticals has remained in a long-term uptrend despite a recent decline.
The stock reached ₹2,047.40 on August 10 before pulling back.
Key support levels are identified at ₹1,850 and ₹1,780.
The recommendation is to buy near ₹1,871 and accumulate near ₹1,800.
The target is ₹2,100, with an initial stop-loss at ₹1,720 and staged adjustments as the price rises.
- Who
- Emcure Pharmaceuticals stock and the technical-analysis recommendation.
- What
- A technical-analysis recommendation to buy the stock, with a target of ₹2,100.
- When
- The market update is dated August 31, 2026; the target is expected before the end of that year.
- Where
- The Indian stock market, including the Sensex, Nifty 50, BSE and NSE context.
- Why
- The stock remains in a long-term uptrend, with support levels at ₹1,850 and ₹1,780 considered intact.
- Stock
- Emcure Pharmaceuticals
- Current price
- ₹1,871.25
- Recent high
- ₹2,047.40 on August 10
- Support levels
- ₹1,850 and ₹1,780
- Buy strategy
- Go long at ₹1,871 and accumulate at ₹1,800
- Initial stop-loss
- ₹1,720
- Profit target
- ₹2,100 before the end of the year